Impax Laboratories Inc. said June 30 it had settled patent litigation with Daiichi Sankyo Inc. and Genzyme Corp. over its proposed generic version of Welchol (colesevelam HCl) tablets and Welchol oral suspension products (Daiichi Sankyo Inc. v. Impax Laboratories Inc.).
Under the settlement, Impax will be allowed to launch its generic tablet product on March 2, 2015, or earlier, under certain circumstances. Impax said the settlement also provides for the launch of the oral suspension products, but those terms were not disclosed. The patent infringement litigation will be dismissed as a result of the settlement.
Genzyme developed Welchol, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.